Literature DB >> 26380089

Immune monitoring technology primer: flow and mass cytometry.

Holden T Maecker1, Alexandre Harari2.   

Abstract

Entities:  

Year:  2015        PMID: 26380089      PMCID: PMC4570613          DOI: 10.1186/s40425-015-0085-x

Source DB:  PubMed          Journal:  J Immunother Cancer        ISSN: 2051-1426            Impact factor:   13.751


× No keyword cloud information.

Description of the technology

Flow cytometry traditionally uses fluorochrome-labeled probes, such as antibodies, to identify cells expressing the targets of those probes. A sample stream carries single cells in suspension past a laser, exciting the fluorochromes, with quantitation of the emitted fluorescent signals from each cell via optical filters and photomultiplier tubes [1]. In mass cytometry, or CyTOF, the fluorescent labels are replaced with heavy metal ions. The metal ions are chelated to a polymer, which is covalently linked to antibodies or other probes. After staining with these probes, single cells are introduced via an aerosol stream into a plasma torch, resulting in complete ionization of the labeled cells. The heavy ions are then focused via a quadrapole and enter a time-of-flight detector, where the individual ions are quantitated [2, 3]. This results in the simultaneous benefit of more available labels, with much less spillover between detector channels (Fig. 1).
Fig. 1

a Example of emission spectra of several dyes used in fluorescence flow cytometry, showing the degree of overlap and consequent spillover between detectors. b Ion signals detected by mass cytometry are by comparison very discrete, allowing many more simultaneous probes to be used, with little or no spillover

a Example of emission spectra of several dyes used in fluorescence flow cytometry, showing the degree of overlap and consequent spillover between detectors. b Ion signals detected by mass cytometry are by comparison very discrete, allowing many more simultaneous probes to be used, with little or no spillover

Type of data obtained/readout

Flow and mass cytometry uniquely allow for the quantitation of multiple parameters on many individual cells. Up to 17 or more parameters are possible with fluorescence, while 40 or more parameters can be quantitated with mass cytometry [4]. It is not unusual to collect data on 105–107 cells per sample by either technique. The data from each sample is compiled in a Flow Cytometry Standard (FCS) file, for both flow and mass cytometry. The FCS file lists the intensities obtained for each probe on each individual cell. Analysis of FCS files can be carried out in any of a number of commercial software packages, and involves sequential “gating” or selection of populations of interest. For example, single cells might first be selected based on light scatter parameters; then live cells gated by exclusion of a viability dye; then lymphocytes identified by a combination of forward and side-angle light scatter; then T cells selected by expression of CD3; etc. Note that mass cytometry does not allow for light scatter properties to be measured, so all gating is done on the basis of labeled probes, in addition to cell length (as measured by the time duration of the cell’s ion cloud). Accurate quantitation of the proportions of even rare populations of cells can be made if enough events are collected; as can relative levels of expression of cellular proteins such as activation markers, intracellular cytokines, or signaling proteins. Absolute cell counts and quantitation of molecules of bound fluorophore/metal are also possible, for example, with reference to standardized labeled beads. Automated gating algorithms are also available, including unsupervised clustering and dimension reduction techniques [5-8].

Limitations of the approach

Pre-conjugated antibodies are now readily available for both flow and mass cytometry, though the latter generally still requires a few conjugates to be made in-house, in order to complete a specific high-parameter panel. Sensitivity to detect low-abundance proteins can be an issue for both platforms. In general, the best fluorochromes have a detection limit of about 40 molecules per cell, while the detection limit for mass cytometry is about 400–500 molecules per cell. Sensitivity is influenced by factors such as autofluorescence (in traditional flow cytometry) and non-specifically bound antibodies (in both platforms). Compensation for spectral overlap can reduce sensitivity and introduce artifacts in fluorescence flow cytometry. In both platforms, there can be loss of cells in sample preparation washing steps, although mass cytometry generally requires more washing steps than fluorescence assays. Additionally, there are cell losses in the mass cytometer itself, such that data are captured on only about 30 % of introduced cells (improved to 50 % in the latest version of CyTOF instrumentation). Collection speed is also much lower in mass cytometry (300–500 events per second, compared to several thousand events/second in fluorescence flow cytometry).

Types of samples needed and special issues pertaining to samples

Cells for these assays need to be in single-cell suspension. Debris and cell aggregates can interfere with the running of samples and with the interpretation of data. Because of the potential for cell loss, samples with <105 cells are usually not appropriate for either flow or mass cytometry. Functional assays, such as cytokine production, or analysis of phospho-signaling proteins, require cells with good viability. Overnight shipping of blood and cryopreservation of PBMC can compromise these readouts. Variability in sample handling, acquisition, and analysis are all significant in affecting results [9]. Multiple approaches can mitigate these factors, from use of lyophilized reagents [10] to “barcoding” of samples to produce a single composite sample for purposes of uniform processing and acquisition [11-13].

Level of evidence

Flow cytometry is backed by thousands of publications and over 30 years of development. Mass cytometry is more recent, but has seen an exponential rise in publications. Several flow cytometry assays are used in FDA-approved diagnostic tests. Both platforms can produce strong evidence, provided that appropriate controls are included.
  12 in total

1.  Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling.

Authors:  Peter O Krutzik; Garry P Nolan
Journal:  Nat Methods       Date:  2006-05       Impact factor: 28.547

Review 2.  Algorithmic Tools for Mining High-Dimensional Cytometry Data.

Authors:  Cariad Chester; Holden T Maecker
Journal:  J Immunol       Date:  2015-08-01       Impact factor: 5.422

Review 3.  An introduction to mass cytometry: fundamentals and applications.

Authors:  Scott D Tanner; Vladimir I Baranov; Olga I Ornatsky; Dmitry R Bandura; Thaddeus C George
Journal:  Cancer Immunol Immunother       Date:  2013-04-07       Impact factor: 6.968

Review 4.  Standardizing immunophenotyping for the Human Immunology Project.

Authors:  Holden T Maecker; J Philip McCoy; Robert Nussenblatt
Journal:  Nat Rev Immunol       Date:  2012-02-17       Impact factor: 53.106

Review 5.  Highly multiparametric analysis by mass cytometry.

Authors:  Olga Ornatsky; Dmitry Bandura; Vladimir Baranov; Mark Nitz; Mitchell A Winnik; Scott Tanner
Journal:  J Immunol Methods       Date:  2010-07-21       Impact factor: 2.303

6.  Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum.

Authors:  Sean C Bendall; Erin F Simonds; Peng Qiu; El-ad D Amir; Peter O Krutzik; Rachel Finck; Robert V Bruggner; Rachel Melamed; Angelica Trejo; Olga I Ornatsky; Robert S Balderas; Sylvia K Plevritis; Karen Sachs; Dana Pe'er; Scott D Tanner; Garry P Nolan
Journal:  Science       Date:  2011-05-06       Impact factor: 47.728

7.  Barcoding of live human peripheral blood mononuclear cells for multiplexed mass cytometry.

Authors:  Henrik E Mei; Michael D Leipold; Axel Ronald Schulz; Cariad Chester; Holden T Maecker
Journal:  J Immunol       Date:  2015-01-21       Impact factor: 5.422

8.  Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE.

Authors:  Peng Qiu; Erin F Simonds; Sean C Bendall; Kenneth D Gibbs; Robert V Bruggner; Michael D Linderman; Karen Sachs; Garry P Nolan; Sylvia K Plevritis
Journal:  Nat Biotechnol       Date:  2011-10-02       Impact factor: 54.908

9.  Standardization of cytokine flow cytometry assays.

Authors:  Holden T Maecker; Aline Rinfret; Patricia D'Souza; Janice Darden; Eva Roig; Claire Landry; Peter Hayes; Josephine Birungi; Omu Anzala; Miguel Garcia; Alexandre Harari; Ian Frank; Ruth Baydo; Megan Baker; Jennifer Holbrook; Janet Ottinger; Laurie Lamoreaux; C Lorrie Epling; Elizabeth Sinclair; Maria A Suni; Kara Punt; Sandra Calarota; Sophia El-Bahi; Gailet Alter; Hazel Maila; Ellen Kuta; Josephine Cox; Clive Gray; Marcus Altfeld; Nolwenn Nougarede; Jean Boyer; Lynda Tussey; Timothy Tobery; Barry Bredt; Mario Roederer; Richard Koup; Vernon C Maino; Kent Weinhold; Giuseppe Pantaleo; Jill Gilmour; Helen Horton; Rafick P Sekaly
Journal:  BMC Immunol       Date:  2005-06-24       Impact factor: 3.615

10.  Critical assessment of automated flow cytometry data analysis techniques.

Authors:  Nima Aghaeepour; Greg Finak; Holger Hoos; Tim R Mosmann; Ryan Brinkman; Raphael Gottardo; Richard H Scheuermann
Journal:  Nat Methods       Date:  2013-02-10       Impact factor: 28.547

View more
  13 in total

1.  SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.

Authors:  Siwen Hu-Lieskovan; Srabani Bhaumik; Kavita Dhodapkar; Jean-Charles J B Grivel; Sumati Gupta; Brent A Hanks; Sylvia Janetzki; Thomas O Kleen; Yoshinobu Koguchi; Amanda W Lund; Cristina Maccalli; Yolanda D Mahnke; Ruslan D Novosiadly; Senthamil R Selvan; Tasha Sims; Yingdong Zhao; Holden T Maecker
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

Review 2.  The role of automated cytometry in the new era of cancer immunotherapy.

Authors:  Marco Danova; Martina Torchio; Giuditta Comolli; Andrea Sbrana; Andrea Antonuzzo; Giuliano Mazzini
Journal:  Mol Clin Oncol       Date:  2018-08-20

Review 3.  The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review.

Authors:  Lisa H Butterfield
Journal:  Semin Cancer Biol       Date:  2017-09-22       Impact factor: 15.707

4.  CyTOF Measurement of Immunocompetence Across Major Immune Cell Types.

Authors:  Priyanka B Subrahmanyam; Holden T Maecker
Journal:  Curr Protoc Cytom       Date:  2017-10-02

Review 5.  Measuring single-cell protein secretion in immunology: Technologies, advances, and applications.

Authors:  Olivia T M Bucheli; Ingibjörg Sigvaldadóttir; Klaus Eyer
Journal:  Eur J Immunol       Date:  2021-04-01       Impact factor: 5.532

6.  CyAnno: A semi-automated approach for cell type annotation of mass cytometry datasets.

Authors:  Abhinav Kaushik; Diane Dunham; Ziyuan He; Monali Manohar; Manisha Desai; Kari C Nadeau; Sandra Andorf
Journal:  Bioinformatics       Date:  2021-05-25       Impact factor: 6.931

Review 7.  Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.

Authors:  Weijie Ma; Barbara M Gilligan; Jianda Yuan; Tianhong Li
Journal:  J Hematol Oncol       Date:  2016-05-27       Impact factor: 17.388

Review 8.  Systematic evaluation of immune regulation and modulation.

Authors:  David F Stroncek; Lisa H Butterfield; Michael A Cannarile; Madhav V Dhodapkar; Tim F Greten; Jean Charles Grivel; David R Kaufman; Heidi H Kong; Firouzeh Korangy; Peter P Lee; Francesco Marincola; Sergio Rutella; Janet C Siebert; Giorgio Trinchieri; Barbara Seliger
Journal:  J Immunother Cancer       Date:  2017-03-21       Impact factor: 13.751

9.  Immunotherapy biomarkers 2016: overcoming the barriers.

Authors:  James L Gulley; Jay A Berzofsky; Marcus O Butler; Alessandra Cesano; Bernard A Fox; Sacha Gnjatic; Sylvia Janetzki; Shyam Kalavar; Vaios Karanikas; Samir N Khleif; Ilan Kirsch; Peter P Lee; Cristina Maccalli; Holden Maecker; Jeffrey Schlom; Barbara Seliger; Janet Siebert; David F Stroncek; Magdalena Thurin; Jianda Yuan; Lisa H Butterfield
Journal:  J Immunother Cancer       Date:  2017-03-21       Impact factor: 13.751

Review 10.  Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Authors:  Sacha Gnjatic; Vincenzo Bronte; Laura Rosa Brunet; Marcus O Butler; Mary L Disis; Jérôme Galon; Leif G Hakansson; Brent A Hanks; Vaios Karanikas; Samir N Khleif; John M Kirkwood; Lance D Miller; Dolores J Schendel; Isabelle Tanneau; Jon M Wigginton; Lisa H Butterfield
Journal:  J Immunother Cancer       Date:  2017-05-16       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.